Systemic immunomodulation & intestinal barrier repair support
Stem cell therapy for Crohn's disease in Istanbul, Turkey
Our Istanbul medical team led by Uzm. Dr. Cihan Bolat evaluates your Crohn's disease history, biomarkers, and endoscopy reports to design an individualized Wharton's jelly MSC and exosome protocol.
Condition-specific editorial anatomy. Explanatory labels remain in accessible text.
Understanding the condition
Understanding the condition and our regenerative approach
Living with Crohn's disease means contending with a deep, relapsing autoimmune process that can affect any layer and segment of the gastrointestinal tract. Inside the bowel wall, overactive immune cells attack the delicate mucosal lining and deeper submucosal tissues, eroding the tight junctions that normally seal the intestinal barrier and triggering persistent abdominal cramping, unpredictable digestive urgency, malabsorption of vital nutrients, and exhausting systemic fatigue that weighs on work, travel, and family life.
Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) and WJ-MSC-derived exosomes are investigated for their ability to address this cycle at the cellular level and help repair the damaged intestinal microenvironment. Once introduced into the circulation, WJ-MSCs sense inflammatory signals and release anti-inflammatory cytokines such as IL-10 and TGF-beta modulators, calming aggressive TNF-alpha, IL-6, and IL-17/IL-23 cascades while shifting tissue-damaging M1 macrophages toward reparative M2 phenotypes and expanding regulatory T-cells (Tregs). Simultaneously, billions of nanoscale WJ-MSC exosomes deliver regenerative microRNAs, hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and insulin-like growth factor (IGF-1) directly to stressed intestinal epithelial crypt cells and microvascular beds — helping rebuild tight-junction barrier proteins, nourish mucosal ulcer repair, and soften fibrotic tissue remodeling.
At our Istanbul clinic, Uzm. Dr. Cihan Bolat and our medical team thoroughly review your colonoscopy reports, pathology, fecal calprotectin, CRP, and medication history to design a personalized WJ-MSC and exosome protocol alongside your home gastroenterologist's care. By combining targeted systemic immunomodulation with cellular trophic support, our goal is to help quiet bowel inflammation, restore digestive comfort, improve nutrient absorption, and support lasting daily vitality.
Reviewed by: Uzm. Dr. Cihan Bolat · Reviewed · Re-review due
What happens inside the body
Key biological processes and therapeutic targets
Crohn's disease is driven by deep transmural immune activation, microvascular stress, and loss of intestinal epithelial integrity. Regenerative medicine targets these upstream cytokine cascades and delivers trophic signals to support cellular repair across the gut wall.
What our protocol aims to support
- Calming mucosal & systemic inflammation: Supporting balanced immune signaling to help reduce the intensity of inflammatory cascades reflected in CRP, ESR, and fecal calprotectin trends.
- Rebuilding intestinal barrier integrity: Delivering paracrine growth factors and extracellular vesicles aimed at nourishing epithelial crypt regeneration and healthier tight-junction homeostasis.
- Improving daily energy & digestive comfort: Helping address systemic inflammatory fatigue, abdominal cramping, and nutritional resilience so patients can participate more fully in daily life.
- Coordinated care alongside your gastroenterologist: Your regenerative protocol in Istanbul is designed to complement — not abruptly replace — the biologic or immunomodulatory medications managed by your home specialist.
- 01
Transmural mucosal immune dysregulation
In Crohn's disease, overactive Th1 and Th17 lymphocytes infiltrate the lamina propria and deeper muscular layers of the intestine, sustaining an autoimmune assault that prevents normal mucosal healing. This deep transmural inflammation causes bowel wall edema, spasmodic pain, and progressive tissue vulnerability. Wharton's jelly MSCs counter this process by secreting prostaglandin E2 (PGE2), indoleamine 2,3-dioxygenase (IDO), and IL-10, which quiet hyperactive effector T-cells and expand protective FoxP3+ regulatory T-cells. By restoring immunologic braking across the gut wall, WJ-MSCs and exosomes help protect deep intestinal layers from continuous inflammatory damage.
- 02
Pro-inflammatory cytokine cascades (TNF-alpha, IL-6, IL-17/23)
High concentrations of TNF-alpha, IL-6, IL-1beta, and IL-23 flood the intestinal microenvironment, recruiting waves of neutrophils and monocytes that erode the mucosal surface and trigger systemic exhaustion. Left unchecked, these cytokine storms also impair iron metabolism, appetite, and restful sleep. WJ-MSCs and their exosomes transfer specific regulatory microRNAs (such as miR-146a and miR-21) that downregulate NF-kappaB inflammatory signaling inside immune and stromal cells. Calming this cytokine surge helps reduce mucosal swelling, ease abdominal cramping, and lift the heavy veil of systemic inflammatory fatigue.
- 03
M1 macrophage activation & submucosal oxidative stress
Intestinal macrophages in active Crohn's disease become trapped in a destructive M1 phenotype, releasing reactive oxygen species (ROS) and matrix metalloproteinases (MMPs) that digest healthy extracellular matrix and delay ulcer closure. Simultaneously, activated submucosal fibroblasts deposit rigid collagen that can gradually narrow the bowel lumen. Bioactive signals from WJ-MSCs and exosomes actively polarize these macrophages into reparative M2 phenotypes that clear cellular debris and secrete tissue-healing factors. This shift reduces local oxidative stress and modulates TGF-beta activity to support softer, healthier tissue remodeling rather than fibrotic scarring.
- 04
Intestinal epithelial barrier & tight-junction breakdown
Healthy digestion relies on a single-cell epithelial lining sealed by tight-junction proteins (claudins, occludin, and ZO-1) and a protective mucin layer. Chronic inflammation strips away this shield and damages Lgr5+ intestinal crypt stem cells, allowing bacterial endotoxins to leak into the submucosa and perpetually re-ignite the immune response. WJ-MSC exosomes deliver epidermal growth factor (EGF), hepatocyte growth factor (HGF), and trophic proteins that stimulate crypt cell regeneration and restore tight-junction integrity. Rebuilding this vital mucosal seal helps normalize fluid and nutrient absorption while shielding underlying immune cells from constant antigenic triggers.
Why regenerative medicine is investigated
Scientific rationale for Wharton's jelly MSCs and exosomes
Targeting Root Transmural Inflammation
Crohn's disease persists when helper T-cells (Th1/Th17) and pro-inflammatory macrophages remain locked in an aggressive signaling loop across the full thickness of the bowel wall. Rather than merely masking digestive symptoms, regenerative medicine is investigated to calm the upstream TNF-alpha, IL-6, and IL-23 cascades that drive recurrent ulceration. By addressing this immune overactivity alongside microvascular ischemia, biological therapy aims to create a calmer internal environment where the intestinal lining can recover. This root-cause focus helps protect healthy bowel architecture and reduce the cumulative tissue strain of chronic flares.
Synergistic Repair by WJ-MSCs & Exosomes
Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) act as dynamic biological regulators that home toward inflamed vascular and lymphoid tissues to rebalance adaptive and innate immunity. They promote the conversion of destructive M1 macrophages into pro-healing M2 macrophages and stimulate regulatory T-cells (Tregs) that restore immune tolerance in the gut. In parallel, WJ-MSC-derived exosomes circulate freely as nanoscale messengers carrying anti-inflammatory microRNAs and trophic growth factors (HGF, VEGF, EGF) directly into intestinal crypt cells. Together, these biologics help repair epithelial tight junctions, nourish damaged submucosal capillaries, and temper fibroblast-driven bowel wall stiffening.
Individualized Protocol Design in Istanbul
Every Crohn's patient presents with a distinct pattern of affected intestinal segments, inflammatory biomarker trends, and prior biologic or surgical history. Before recommending treatment, Uzm. Dr. Cihan Bolat and our medical team evaluate your recent endoscopy, MRI enterography, fecal calprotectin, CRP, and nutritional labs in detail. Based on this clinical profile, we tailor the exact GMP-certified WJ-MSC cell dosage, exosome concentration, and delivery routes to match your disease activity safely alongside your ongoing gastroenterologist-prescribed medications. Structured 1, 3, and 6-month follow-up reviews then track your biomarkers and digestive comfort over time.
Our treatment approach & administration routes
How our proposed Wharton's jelly MSC and exosome protocols work
- 01
Intravenous Wharton's Jelly MSC (WJ-MSC) Infusion
Intravenous infusion delivers high-viability, GMP-certified Wharton's jelly mesenchymal stem cells into the systemic circulation, where they interact with circulating and lymphoid immune populations. Through paracrine secretion of IL-10, PGE2, and trophic growth factors, these young, immunoprivileged cells help downregulate overactive Th1/Th17 responses and convert pro-inflammatory M1 macrophages into tissue-repairing M2 macrophages. This systemic immunomodulation targets the deep transmural inflammatory cascades driving Crohn's flares and supports microvascular perfusion within the mesenteric and submucosal blood vessels. It serves as the foundational route for addressing widespread luminal inflammation and systemic fatigue.
Role in your protocolOur medical team determines the exact Wharton's jelly MSC and exosome combination, dosage, and administration route after evaluating your medical history and reports.
- 02
Intravenous WJ-MSC-Derived Exosome Administration
WJ-MSC-derived exosomes are nanoscale extracellular vesicles (30–150 nm) that easily cross biological barriers without pulmonary trapping, delivering a concentrated payload of anti-inflammatory microRNAs, antioxidant enzymes, and epithelial growth factors (HGF, VEGF, IGF-1). Inside the gut wall, exosomes are taken up by stressed intestinal epithelial cells, endothelial cells, and lamina propria immune cells to help restore tight-junction proteins and accelerate mucosal ulcer repair. They work alongside WJ-MSCs to provide both rapid vesicular signaling and sustained cellular regulation. We note transparently that while preclinical and early clinical data highlight strong mechanistic synergy, whether combined MSC and exosome therapy outperforms single-modality treatment remains under active clinical study.
Role in your protocolOur medical team determines the exact Wharton's jelly MSC and exosome combination, dosage, and administration route after evaluating your medical history and reports.
- 03
Intramuscular Administration (When Included in Your Protocol)
In selected Crohn's protocols, our physicians incorporate intramuscular administration alongside intravenous delivery to take advantage of the biological 'depot effect.' Whereas intravenously infused MSCs experience significant initial first-pass retention in the pulmonary capillary bed, cells placed within well-vascularized muscle tissue remain locally viable for a longer window and release a steady stream of immunomodulatory cytokines and trophic vesicles into the systemic circulation. This sustained paracrine release helps extend anti-inflammatory support for the intestinal mucosa between infusion sessions. We clearly distinguish this biological depot rationale from established clinical trial proof of pharmacokinetic superiority.
Role in your protocolOur medical team determines the exact Wharton's jelly MSC and exosome combination, dosage, and administration route after evaluating your medical history and reports.
What we aim to achieve
Therapeutic objectives and functional outcomes we track
Before treatment in Istanbul, our physicians establish your clinical baseline and define realistic biological and functional objectives to track during follow-up.
- 01
Mucosal Healing & Inflammatory Biomarkers
By calming TNF-alpha and IL-6 cascades and supporting epithelial crypt repair, our protocol aims to support healthier fecal calprotectin, CRP, and ESR trends alongside improved mucosal appearance on follow-up evaluations with your home gastroenterologist.
- 02
Digestive Comfort & Bowel Regularity
Restoring tight-junction barrier integrity and reducing bowel wall edema helps ease daily abdominal cramping, reduce stool urgency and frequency, and bring greater predictability to your meals and daily schedule.
- 03
Nutrient Absorption & Metabolic Vitality
As mucosal ulceration calms and villous/epithelial function improves, the digestive tract is better able to absorb iron, vitamin B12, vitamin D, and proteins, supporting healthier hemoglobin and albumin levels.
- 04
Sustained Daily Energy & Quality of Life
Quieting chronic systemic cytokine activity helps lift deep inflammatory exhaustion, improve sleep restoration, and restore the physical stamina needed for work, travel, and social life.
How treatment is personalized
How our medical team evaluates your records and designs your protocol
Our Istanbul medical team led by Uzm. Dr. Cihan Bolat evaluates your Crohn's disease history, biomarkers, and endoscopy reports to design an individualized Wharton's jelly MSC and exosome protocol.
Medical history & reports we request
- Confirmed Crohn's disease diagnosis, affected segments, and clinical history
- Recent colonoscopy or enterography reports and pathology findings
- Baseline laboratory results including CRP, ESR, CBC, and fecal calprotectin
- Current and prior biologic, immunomodulator, or corticosteroid medications
- Nutritional labs (iron, vitamin B12, vitamin D, albumin) and symptom log
Clinical suitability & protocol checks
- Patients continue their prescribed Crohn's medications as directed by their home gastroenterologist before and after visiting Istanbul.
- Any acute bowel obstruction, active intra-abdominal abscess, or severe febrile flare must be stabilized locally before international travel.
- Your written proposal details the exact GMP-certified WJ-MSC cell count, exosome dosage, administration schedule, and 1, 3, and 6-month follow-up plan.
What the patient journey looks like
From your first inquiry to individualized treatment in Istanbul
- 01
Contact us & share your medical reports
Reach out regarding your condition and share your medical history, diagnosis, imaging, and relevant lab reports via our secure form or WhatsApp.
- 02
Medical team evaluation & protocol design
Our medical team evaluates your records and, where clinically appropriate, develops an individualized Wharton's jelly MSC and exosome protocol.
- 03
Transparent explanation of protocol & costs
We explain the proposed treatment, specific biologics, administration routes, intended therapeutic objectives, stay timeline, and itemized costs.
- 04
Arrange treatment in Istanbul & follow-up
Review your individualized proposal, schedule your visit to Istanbul with private airport and clinic transfers, and continue with structured 1, 3, and 6-month follow-up.
2026 cost & protocol planning
Transparent Istanbul pricing tailored to your protocol
After our medical team evaluates your records, we provide a written proposal explaining the recommended Wharton's jelly MSC and exosome preparations, administration routes, intended objectives, stay timeline, and itemized costs.
For 2026 planning context, targeted exosome and local orthopedic protocols typically range from $3,500–$6,500, while comprehensive Wharton's jelly MSC and exosome programs range from $7,000–$18,000. Your exact cost is confirmed after your medical evaluation.
- Patients continue their prescribed Crohn's medications as directed by their home gastroenterologist before and after visiting Istanbul.
- Any acute bowel obstruction, active intra-abdominal abscess, or severe febrile flare must be stabilized locally before international travel.
- Your written proposal details the exact GMP-certified WJ-MSC cell count, exosome dosage, administration schedule, and 1, 3, and 6-month follow-up plan.
What your written treatment proposal explains
- 01
Which Wharton's jelly MSC, exosome, or combined protocol is proposed for your condition?
- 02
Which administration routes are recommended and how do they work biologically?
- 03
What are the intended therapeutic objectives and expected stay length in Istanbul?
- 04
What is the itemized cost and how does 1, 3, and 6-month follow-up work after treatment?
Evidence & important considerations
Published clinical research and important considerations
Below is a summary of published human studies, investigated mechanisms, and important limitations relevant to regenerative medicine for this condition.
01 Mesenchymal stromal cells in Crohn's disease clinical research
Open study- Product
- Allogeneic mesenchymal stromal cells and umbilical cord / Wharton's jelly MSCs
- Route
- Systemic intravenous infusion and localized clinical research pathways
- Study design
- Randomized confirmatory phase 3 trial and translational immunomodulation research
- Finding
- Clinical studies investigate MSC immunomodulatory signaling in refractory Crohn's phenotypes, while the confirmatory ADMIRE-CD II local fistula trial did not show superiority over placebo.
- Limitation
- Outcomes depend on disease phenotype, cell source, and route of administration, and regenerative protocols remain supportive rather than a standalone replacement for gastroenterology care.
Scientific references
Clinical studies and scientific references
FAQ
Frequently asked questions about this treatment
Request Free Medical Evaluation
Begin a personalized treatment conversation with our medical team.
Share your case in confidence. Our international coordinators review every enquiry and respond within 24 hours, in your language.